Modern Fertility, Inc.

Modern Fertility, Inc. is a reproductive health company focused on providing accessible fertility insights through home testing kits, aimed at empowering individuals to understand their reproductive health better. Founded in 2017 in San Francisco, US, Modern Fertility, Inc. specializes in reproductive health products.

The company was acquired by Roman Health Medical LLC in May 2021 for USD 225 mn in stock. The co-founders, Afton Vechery and Tom Chokel, have been instrumental in steering the company towards offering innovative fertility solutions. Modern Fertility, now part of Ro, specializes in reproductive health products aimed at empowering individuals with actionable insights regarding their fertility. The company's core offerings include hormone and fertility tests, ovulation tests, pregnancy tests, and prenatal vitamins, all designed to be conducted from the comfort of home.

These products cater primarily to individuals and couples interested in understanding their fertility health, whether they are planning to conceive now or in the future. Modern Fertility's hormone tests provide personalized reports based on individual hormone levels, supporting users in making informed decisions about their reproductive health. Their services are available primarily in the United States, with a focus on expanding access to reproductive health information for a diverse client base, including women and men of reproductive age. The revenue model of Modern Fertility is built around direct-to-consumer transactions, primarily through the sale of its fertility testing kits and related health products.

Customers can purchase individual tests or opt for bundled services, which may include personalized reports and access to additional resources via a subscription model. This structure allows users to receive ongoing support as they navigate their fertility journey. Flagship products include the Modern Fertility Hormone Test, which provides insights into ovarian reserve, and fertility tracking tools that help users understand their cycle and fertile window. Through these offerings, Modern Fertility engages its clientele in meaningful ways, facilitating proactive management of reproductive health.

Following the acquisition in May 2021, Modern Fertility plans to utilize the USD 225 mn funding to enhance its product offerings and expand into new markets. The company is developing new products aimed at improving reproductive health insights, with specific launches planned for the upcoming years. Additionally, Modern Fertility aims to broaden its reach within the US market and explore opportunities in international markets, particularly focusing on Europe and Asia by 2023.